Tyler Van Buren
Stock Analyst at TD Cowen
(2.37)
# 2,553
Out of 5,182 analysts
63
Total ratings
45.1%
Success rate
-0.18%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Maintains: Buy | $15 → $30 | $9.80 | +206.12% | 4 | Mar 11, 2026 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $120 → $85 | $39.49 | +115.24% | 1 | Feb 26, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $30 → $35 | $23.63 | +48.12% | 1 | Feb 26, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Hold | $40 → $45 | $49.51 | -9.11% | 3 | Feb 13, 2026 | |
| CCCC C4 Therapeutics | Initiates: Buy | n/a | $2.82 | - | 1 | Dec 2, 2025 | |
| MBX MBX Biosciences | Initiates: Buy | n/a | $32.99 | - | 1 | Nov 4, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $30 → $40 | $30.44 | +31.41% | 2 | Oct 31, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $60 → $95 | $73.15 | +29.87% | 2 | Oct 30, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $115 → $125 | $139.71 | -10.53% | 6 | Oct 23, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Buy | n/a | $32.74 | - | 1 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $67.48 | - | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $12.00 | - | 2 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $21.47 | - | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $53.31 | - | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $70 → $60 | $49.20 | +21.95% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $6.74 | - | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $6.26 | - | 1 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,030 → $1,200 | $761.85 | +57.51% | 7 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $30.52 | - | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $32.99 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $47.58 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $114.77 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $84.34 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.22 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $30.83 | +127.05% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.63 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.85 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $39.61 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $225 | $19.40 | +1,059.79% | 1 | Feb 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $7.97 | +10,878.67% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $15.51 | +157.90% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $16.02 | +87.27% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.35 | +3,603.70% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.37 | +8,008.11% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.90 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $30.08 | - | 1 | Aug 4, 2017 |
Biohaven
Mar 11, 2026
Maintains: Buy
Price Target: $15 → $30
Current: $9.80
Upside: +206.12%
Soleno Therapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $120 → $85
Current: $39.49
Upside: +115.24%
Arcutis Biotherapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $30 → $35
Current: $23.63
Upside: +48.12%
CRISPR Therapeutics AG
Feb 13, 2026
Maintains: Hold
Price Target: $40 → $45
Current: $49.51
Upside: -9.11%
C4 Therapeutics
Dec 2, 2025
Initiates: Buy
Price Target: n/a
Current: $2.82
Upside: -
MBX Biosciences
Nov 4, 2025
Initiates: Buy
Price Target: n/a
Current: $32.99
Upside: -
Travere Therapeutics
Oct 31, 2025
Maintains: Buy
Price Target: $30 → $40
Current: $30.44
Upside: +31.41%
BridgeBio Pharma
Oct 30, 2025
Maintains: Buy
Price Target: $60 → $95
Current: $73.15
Upside: +29.87%
Gilead Sciences
Oct 23, 2025
Maintains: Buy
Price Target: $115 → $125
Current: $139.71
Upside: -10.53%
IDEAYA Biosciences
Jul 22, 2025
Initiates: Buy
Price Target: n/a
Current: $32.74
Upside: -
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $67.48
Upside: -
Dec 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $12.00
Upside: -
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $21.47
Upside: -
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $53.31
Upside: -
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $49.20
Upside: +21.95%
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $6.74
Upside: -
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $6.26
Upside: -
Jul 23, 2024
Maintains: Buy
Price Target: $1,030 → $1,200
Current: $761.85
Upside: +57.51%
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $30.52
Upside: -
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $32.99
Upside: -
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $47.58
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $114.77
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $84.34
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.22
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $30.83
Upside: +127.05%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $2.63
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.85
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $39.61
Upside: -
Feb 10, 2021
Initiates: Overweight
Price Target: $225
Current: $19.40
Upside: +1,059.79%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $7.97
Upside: +10,878.67%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $15.51
Upside: +157.90%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $16.02
Upside: +87.27%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $1.35
Upside: +3,603.70%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $0.37
Upside: +8,008.11%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $10.90
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $30.08
Upside: -